Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

被引：24

作者：

Lingscheid, Tilman ^{[1
,2
,3
]}

Kinzig, Martina ^{[4
]}

Krueger, Anne ^{[2
,3
,5
]}

Mueller, Nils ^{[2
,3
,5
]}

Boelke, Georg ^{[2
,3
,5
]}

Tober-Lau, Pinkus ^{[1
,2
,3
]}

Muenn, Friederike ^{[1
,2
,3
]}

Kriedemann, Helene ^{[1
,2
,3
]}

Witzenrath, Martin ^{[1
,2
,3
,6
]}

Sander, Leif E. ^{[1
,2
,3
,6
,7
]}

Soergel, Fritz ^{[4
,8
]}

Kurth, Florian ^{[1
,2
,3
,9
]}

机构：

[1] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] IBMP Inst Biomed & Pharmaceut Res, Nurnberg, Germany

[5] Charite Univ Med Berlin, Dept Nephrol & Intens Care, Berlin, Germany

[6] DZL, German Ctr Lung Res, Berlin, Germany

[7] Berlin Inst Hlth, Berlin, Germany

[8] Univ Duisburg Essen, West German Heart & Vasc Ctr, Inst Pharmacol, Essen, Germany

[9] Bernhard Nocht Inst Trop Med, Dept Trop Med, Hamburg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 11期

关键词：

COVID-19; end-stage renal disease; hemodialysis; nirmatrelvir/ritonavir; Paxlovid; PLASMA;

D O I：

10.1128/aac.01229-22

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/ mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.

引用

页数：4

共 50 条

[1] Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis
Soergel, Fritz
Malin, Jakob J.
Hagmann, Henning
Kinzig, Martina
Bilal, Muhammad
Eichenauer, Dennis A.
Scherf-Clavel, Oliver
Simonis, Alexander
El Tabei, Lobna
Fuhr, Uwe
Rybniker, Jan
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (03) : 825 - 827
[2] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
Lu, Jiayue
Cai, Hong
Hao, Yujun
Lin, Zhang
Liu, Shang
Zhan, Yaping
Ding, Li
Huang, Meilan
Li, Zhenyuan
Xu, Lan
Yan, Xiujuan
Yang, Li
Zhang, He
Zhang, Wei
Zhao, Li
Zhao, Junli
Wang, Ting
Gu, Leyi
FRONTIERS IN PHARMACOLOGY, 2023, 14
[3] A Retrospective Study of End-Stage Renal Disease Patients on Maintenance Hemodialysis with COVID-19
Lakshmi, P. Aiswharya
Sunnesh, A.
Mathini, S.
Kumar, Prasanna N.
Gurupriya, M.
Naveen, K.
Rao, G. Vishwaeswar
Srilakshmi, G.
Amarendra, M. Raja
Bhatt, G. Gayathri
Manuel, Maria Bethasida
Kumar, V. Kiran
Reddy, K. Dinakar
Kumar, B. Anil
Bhanu, S. Taranum
Alekhya, B.
Charishma, G.
Soundarya, S.
Thulasi, G. Ram
Bhargav, P.
Sailaja, S.
Ram, R.
Kumar, V. Siva
Vengamma, B.
INDIAN JOURNAL OF NEPHROLOGY, 2024, 34 (03) : 252 - 253
[4] Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: An absolute contraindication?
Haddad, Issa
Agarwal, Priyal
Hassanein, Mohamed
THERAPEUTIC APHERESIS AND DIALYSIS, 2022, 26 (04) : 850 - 851
[5] PHARMACOKINETICS AND PHARMACODYNAMICS OF EVOGLIPTIN IN END-STAGE RENAL DISEASE PATIENTS ON HEMODIALYSIS
Kim, B.
Yu, K.
Lee, S.
Oh, J.
Jang, I.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S67 - S67
[6] THE PHARMACOKINETICS OF AMINOGUANIDINE IN END-STAGE RENAL-DISEASE PATIENTS ON HEMODIALYSIS
FOOTE, EF
LOOK, ZM
GILES, P
KEANE, WF
HALSTENSON, CE
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (03) : 420 - 425
[7] Safety of Nirmatrelvir/Ritonavir in Dialysis Patients with COVID-19 The End of the Beginning?
Yilmam, Osman A. A.
Leaf, David E. E.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (04): : 427 - 429
[8] Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis
Lee, Jacqueline
Steel, Jennifer
Roumelioti, Maria-Eleni
Erickson, Sarah
Myaskovsky, Larissa
Yabes, Jonathan G.
Rollman, Bruce L.
Weisbord, Steven
Unruh, Mark
Jhamb, Manisha
KIDNEY360, 2020, 1 (12): : 1390 - 1397
[9] Impact of the COVID-19 pandemic on the management of patients with end-stage renal disease
Li, Szu-Yuan
Tang, Yu-Shuo
Chan, Yu-Jiun
Tarng, Der-Cherng
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (07) : 628 - 633
[10] THE EFFECT OF HEMODIALYSIS ON THE PHARMACOKINETICS OF TENOXICAM IN PATIENTS WITH END-STAGE RENAL-DISEASE
ALGHAMDI, MS
ALMOHANNA, FA
ALMUSTAFA, ZH
ALSAEED, IS
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (02) : 197 - 199

← 1 2 3 4 5 →